<DOC>
	<DOCNO>NCT00053898</DOCNO>
	<brief_summary>RATIONALE : Estrogen stimulate growth breast cancer cell . Tamoxifen may fight breast cancer block use estrogen . Anastrozole may fight breast cancer decrease estrogen production . It yet know whether anastrozole effective tamoxifen prevent recurrence breast cancer . PURPOSE : This randomized phase III trial study anastrozole see well work compare tamoxifen prevent recurrence breast cancer postmenopausal woman ductal carcinoma situ undergo lumpectomy radiation therapy .</brief_summary>
	<brief_title>Anastrozole Tamoxifen Treating Postmenopausal Women With Ductal Carcinoma Situ Who Are Undergoing Lumpectomy Radiation Therapy</brief_title>
	<detailed_description>OBJECTIVES : - Compare value anastrozole v tamoxifen , term prevent recurrence ( i.e. , local , regional , distant recurrence contralateral breast cancer ) , lumpectomy radiotherapy postmenopausal woman ductal carcinoma situ ( DCIS ) . - Compare subsequent disease occurrence , term invasive breast cancer ( local , regional , distant , contralateral ) , ipsilateral contralateral breast cancer ( invasive DCIS ) , non-breast second primary malignancy , patient treat drug . - Compare quality life symptom patient treat drug . * - Compare quality-adjusted survival time patient treat drug . * - Compare occurrence osteoporotic fracture patient treat drug . - Compare disease-free overall survival patient treat drug . NOTE : *The quality life study close accrual 12/28/04 . OUTLINE : This randomize , double-blind , placebo-controlled , multicenter study . Patients stratify accord age ( 60 vs 60 ) . Patients randomize 1 2 treatment arm ( arm I arm II close accrual 6/15/06 ) . - Arm I ( close accrual 6/15/06 ) : Patients receive oral tamoxifen oral placebo daily 5 year . - Arm II ( close accrual 6/15/06 ) : Patients receive oral anastrozole oral placebo daily 5 year . Beginning within 8 week randomization , patient also undergo whole breast radiotherapy , unless patient enrol protocol NSABP-B-39 randomize partial breast irradiation group . Patients follow every 6 month 5 year , annually thereafter . For patient enrol quality life study , quality life assess baseline every 6 month 6 year . * NOTE : *The quality life study close accrual 12/28/04 . PROJECTED ACCRUAL : A total 3,000 patient ( 1,500 per treatment arm ) accrue study within 5 year ( arm I arm II close accrual 6/15/06 ) .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Carcinoma , Ductal</mesh_term>
	<mesh_term>Carcinoma , Intraductal , Noninfiltrating</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm ductal carcinoma situ ( DCIS ) breast Mixed DCIS lobular carcinoma situ ( LCIS ) allow Must undergone lumpectomy Margins must histologically free disease Reexcision obtain tumorfree margin allow No 84 day since prior lumpectomy reexcision More 1 area DCIS allow provided disease remove tumorfree margin Masses cluster calcification clinically mammographically suspicious must biopsied No prior invasive breast cancer DCIS Patients history LCIS eligible No prior concurrent invasive ( include microinvasive ) breast cancer DCIS `` suspicious '' microinvasion allow No bilateral malignancy No mass mammographic abnormality suspicious malignancy opposite breast unless malignant proven biopsy No Paget 's disease nipple No positive ipsilateral axillary intramammary node No palpable node ipsilateral contralateral axilla palpable supraclavicular infraclavicular node unless involve tumor proven biopsy Hormone receptor status : Estrogen progesteronereceptor positive determine immunohistochemistry Borderline result consider positive PATIENT CHARACTERISTICS : Age See Menopausal status Sex : Female Menopausal status : Postmenopausal define least 1 following : Prior document bilateral oophorectomy At least 12 month without spontaneous bleed Age 55 prior hysterectomy without oophorectomy Age 54 prior hysterectomy without oophorectomy document folliclestimulating hormone level postmenopausal range Performance status Zubrod 02 Life expectancy At least 10 year ( exclude diagnosis breast cancer ) Hematopoietic WBC normal Hepatic AST normal Bilirubin normal Alkaline phosphatase normal No hepatic disease would preclude administration study drug Renal Creatinine normal No renal disease would preclude administration study drug Cardiovascular No prior document cerebral vascular accident transient ischemic attack No prior deep vein thrombosis No cardiovascular disease would preclude administration study drug No uncontrolled hypertension ( i.e. , systolic blood pressure least 180 mm Hg diastolic blood pressure least 110 mm Hg base average 2 reading 2 visit initial screen ) No uncontrolled atrial fibrillation Pulmonary No pulmonary embolus Other Not pregnant nursing Patients history nonbreast malignancy eligible provide diseasefree â‰¥ 5 year deem physician low risk recurrence No malignancy within past 5 year except treat basal cell squamous cell skin cancer , carcinoma situ cervix , carcinoma situ colon , melanoma situ No psychiatric addictive disorder would preclude informed consent No uncontrolled diabetes , define hemoglobin A1C great 9 % ( fast glucose 200 mg/dL ) No nonmalignant systemic disease would preclude administration study drug PRIOR CONCURRENT THERAPY : Endocrine therapy No prior concurrent aromatase inhibitor ( e.g. , exemestane letrozole ) tamoxifen No concurrent raloxifene selective estrogen receptor modulators No concurrent sex hormone therapy ( e.g. , estrogen progesterone replacement therapy , oral contraceptive , androgen , luteinizing hormone release hormone analog , prolactin inhibitor , antiandrogens ) Lowdose estrogen vaginal cream Estring allow Radiotherapy Radiotherapy cancer initiate study allow Surgery See Disease Characteristics No prior concurrent mastectomy DCIS Prior sentinel node biopsy axillary node dissection allow provide node pathologically negative Other No concurrent warfarin No systemic therapy cancer initiate study No concurrent anticancer therapy unless permit protocol investigator No concurrent participation another clinical trial therapy DCIS Concurrent participation protocol NSABPB39 allow</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>breast cancer situ</keyword>
	<keyword>ductal breast carcinoma situ</keyword>
</DOC>